For most of 2024, I was the primary caregiver for my grandmother during her cancer treatment. She had light chain nephropathy — a hematologic malignancy monitored through serum kappa light chain levels and treated with chemotherapy, steroids, and dialysis. I took her to oncology four or five days a week while working remotely as a software architect. Her treatment team did remarkable work, and she had an extraordinary clinical response.
What I learned in those months changed how I thought about cancer care.
Modern oncology has made stunning advances — targeted therapies, genomic profiling, biomarker-driven treatment selection. But the information that drives every treatment decision lives in 500-page reports that busy oncologists rarely have time to read carefully. Meaningful details get missed. Coordination between specialists runs on caregivers forwarding PDFs. The gap between what precision oncology could be and what it often is isn't a science problem. It's an information design problem.
UNMIRI is built to close that gap. We take the 500-page genomic report a lab sends to an oncologist and turn it into a 2-page actionable dashboard — top recommendations with evidence levels, contraindications flagged, matched clinical trials, every claim cited. The lab keeps the oncologist. The oncologist gets their time back. The patient gets better care.
This is the tool I wish my grandmother's oncologists had had. I'm building it so other families can have it.
— Umair Khan, Founder
Team
UNMIRI is led by Umair Khan — technology executive, caregiver, founder. The company is actively recruiting a clinical advisor (oncologist or pathologist with NGS interpretation experience).
If that's you, reach out at hello@unmiri.com.
How we work
UNMIRI is built with a preference for deterministic, inspectable systems where clinical safety matters. The knowledge graph is queryable. The templates are testable. Use of language models is narrow and clearly bounded. UNMIRI doesn't treat “AI” as a black box clinicians are asked to trust — it's one tool in a pipeline that is, as a whole, accountable to the clinicians who use it.
More on the technical approach at /product.
Where we are
UNMIRI is bootstrapped. The evidence graph currently queries OncoKB, ClinVar, ClinicalTrials.gov, and AACR Project GENIE, with additional authoritative oncology sources integrated as pilot partners require them. The Q2 2026 cohort is actively onboarding 2–3 regional diagnostic labs in the mid-Atlantic as retrospective design partners.
If you run or work at a diagnostic lab and want to see what we've built, get in touch.
Company information
UNMIRI LLC is a Pennsylvania limited liability company formed in August 2023, headquartered in Langhorne, Pennsylvania. Pennsylvania Entity #0013556484.
Press inquiries: hello@unmiri.com (subject line: Press).